Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial

被引：0
|
作者：
Bajaj, Jasmohan [1 ]
Yeramian, Patrick [2 ]
Gavis, Edith [1 ]
Fagan, Andrew [1 ]
Fischer, James [3 ]
Garcia-Tsao, Guadalupe [4 ]
Angeli, Paolo [5 ]
Smith, Denise [2 ]
Adams, Jonathan [2 ]
Markham, Penelope [2 ]
机构：
[1] Hunter Holmes McGuire VA Ctr, Richmond, VA USA
[2] BioVie Inc, Los Angeles, CA USA
[3] Univ Illinois, Coll Pharm, Chicago, IL USA
[4] Yale Sch Med, New Haven, CT USA
[5] Univ Padua, Med, Padua, Italy
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT139
引用
收藏
页码：S718 / S719
页数：2
相关论文
共 50 条
  • [41] A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients.
    Chu, Q
    Goldstein, L
    Murray, N
    Rowinsky, E
    Cianfrocca, M
    Gale, M
    Ho, P
    Paul, E
    Loftiss, J
    Pandite, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [42] Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
    Kumler, I.
    Sorensen, P. Grundtvig
    Palshof, J.
    Hogdall, E.
    Skovrider-Ruminski, W.
    Theile, S.
    Fullerton, A.
    Nielsen, P. G.
    Jensen, B. Vittrup
    Nielsen, D. L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (01) : 169 - 178
  • [43] An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors
    Hajime Asahina
    Yosuke Tamura
    Hiroshi Nokihara
    Noboru Yamamoto
    Yoshitaka Seki
    Takashi Shibata
    Yasushi Goto
    Maki Tanioka
    Yasuhide Yamada
    Andrew Coates
    Yi-Lin Chiu
    Xiaohui Li
    Rajendra Pradhan
    Peter J. Ansell
    Evelyn M. McKeegan
    Mark D. McKee
    Dawn M. Carlson
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1477 - 1486
  • [44] Safety, tolerability, and efficacy of adjunctive lacosamide in pediatric patients with epilepsy syndromes associated with generalized seizures: Phase 2, open-label exploratory trial
    Auvin, Stephane
    Arzimanoglou, Alexis
    Beller, Cynthia
    Floricel, Florin
    Daniels, Tony
    Bozorg, Ali
    EPILEPSIA, 2023, 64 (11) : 2947 - 2957
  • [45] Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial
    Leem, Galam
    Jang, Sung Ill
    Cho, Jae-Hee
    Jo, Jung Hyun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Yoo, Da-Kyung
    Cheon, Hyo-Cheon
    Kim, Jae-Eun
    Lim, Kyeong-Pill
    Jung, In-Hye
    Im, Jung-Min
    Chung, Yong Yoon
    Park, Seung Woo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial
    Leem, Galam
    Jang, Sung-Ill
    Cho, Jae-Hee
    Jo, Jung Hyun
    Lee, Hee Seung
    Chung, Moon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Yoo, Da-Kyung
    Cheon, Hyo-Cheon
    Kim, Jae-Eun
    Lim, Kyeong-Pill
    Jung, In-Hye
    Im, Jung-Min
    Chung, Yong-Yoon
    Park, Seung Woo
    CANCERS, 2022, 14 (17)
  • [47] OPEN PROSPECTIVE TRIAL INVESTIGATING PHARMACOKINETICS, TOLERABILITY AND SAFETY OF A NEW 10% HUMAN IMMUNOGLOBULIN FOR INTRAVENOUS INFUSION (IVIG) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASE
    Krivan, G.
    Koenigs, C.
    Bernatowska, E.
    Marodi, L.
    Erdos, M.
    Salama, A.
    Linde, R.
    JOURNAL OF CLINICAL IMMUNOLOGY, 2012, 32 : 154 - 154
  • [48] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Ghamande, Sharad
    Lin, Chia-Chi
    Cho, Daniel C.
    Shapiro, Geoffrey I.
    Kwak, Eunice L.
    Silverman, Michael H.
    Tseng, Yunlong
    Kuo, Min-Wen
    Mach, Wendy B.
    Hsu, Shu-Chi
    Coleman, Teresa
    Yang, James Chih-Hsin
    Cheng, Ann-Lii
    Ghalib, Mohammad H.
    Chuadhary, Imran
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 445 - 451
  • [49] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Sharad Ghamande
    Chia-Chi Lin
    Daniel C. Cho
    Geoffrey I. Shapiro
    Eunice L. Kwak
    Michael H. Silverman
    Yunlong Tseng
    Min-Wen Kuo
    Wendy B. Mach
    Shu-Chi Hsu
    Teresa Coleman
    James Chih-Hsin Yang
    Ann-Lii Cheng
    Mohammad H. Ghalib
    Imran Chuadhary
    Sanjay Goel
    Investigational New Drugs, 2014, 32 : 445 - 451
  • [50] Safety and Efficacy of Continuous Apomorphine Infusion in Patients with Parkinson's disease: Results from a Phase 3, Open-label Study
    Isaacson, Stuart
    Espay, Alberto
    Pahwa, Rajesh
    Clinch, Thomas
    LeWitt, Peter
    NEUROLOGY, 2020, 94 (15)
12345